DEVELOPMENT OF NOVEL ANALYTICAL AND DIAGNOSTIC TOOLS USING NANOTECHNOLOGY AND MICROFLUIDICS
With
Dr Alain Wuethrich
NHMRC Emerging Leader Fellow
Australian Institute for Bioengineering and Nanotechnology,
The University of Queensland
Brisbane, Australia
RESEARCHER PROFILE
Filmed in Brisbane | June 2025
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
A feature of his work has been the ability to translate discoveries at the nanoscale into highly innovative diagnostics that enable the precise study of biomolecular aberrations in cancer, infectious diseases, and human immune system.
His particular research expertise lies in:
– Liquid biopsy
– Electrohydrodynamics
– Surface-enhanced Raman spectroscopy
– Nanotechnology
– Diagnostics
Dr Wuethrich held positions in international pharmaceutical companies and became lead inventor on a European patent.
He has actively engaged with national and international companies to translate diagnostic nanotechnologies. His network of national and international collaborators include the Princess Alexandra Hospital, UQ Diamantina Institute, UQ Centre for Clinical Research, QIMR Berghofer, and the Dana-Farber Cancer Institute.
Since 2017 he has provided continuous research mentoring to the group and has supervised more than 30 postgraduate and graduate students in nanotechnological strategies to detect cancer and other diseases.
In May 2024 Dr Wuethrich won a $1.6 million NHMRC Emerging Leader 2 grant to develop digital nanotechnology capable of detecting trace immune dysregulation from a pin-prick of blood.
He says understanding immune dysregulation is crucial for addressing emerging diseases like Long Covid and for future-proofing immune-modulating mRNA vaccines.
“The technology we have in mind will be 1000 times more sensitive than conventional methods,” Dr Wuethrich said.
“Hopefully, this will lead to a better understanding, diagnosis, and treatment of diseases like long COVID, and the development of personalised vaccines with greatly reduced side effects.”
Dr Wuethrich is one of two Investigator Grant winners currently working with Professor Matt Trau.
Source: Supplied
-
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
-
Impact of Leukaemia Foundation’s Research Funding into Blood Cancer
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
